Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
Titel:
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
Auteur:
Necchi, Andrea Raggi, Daniele Giannatempo, Patrizia Marandino, Laura Farè, Elena Gallina, Andrea Colecchia, Maurizio Lucianò, Roberta Salonia, Andrea Gandaglia, Giorgio Fossati, Nicola Bandini, Marco Pederzoli, Filippo Dittamore, Ryan Liu, Yang Davicioni, Elai Ross, Jeffrey S. de Jong, Joep J. Briganti, Alberto Montorsi, Francesco Gibb, Ewan A.